Cusatuzumab

N/A

Report date: 2026/05/12 20:00:17

Base Information

Drug NameCusatuzumab
Drug Alias NameAnti-CD70 SIMPLE AntibodyJNJ-4550ARGX-110
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsAnti-CD70
TargetsCD70 antigen
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[17] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesArgenx Se
China Registration ClassN/A

Develop Information

Active CompaniesOncoVerity IncArgenx SeJanssen Pharmaceutical Kk +[4] 
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Inactive IndicationsLeukemia, Myelomonocytic, ChronicNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A